Clinical and Hematological Evaluation of Patients with Sickle Cell Anemia Before and After Four Years of Using Hydroxyurea

  • Ieda Maria Gonçalves Pacce Bispo
  • Maria Lúcia Ivo
  • Valter Aragão do Nascimento
  • Alexandra Maria Almeida Carvalho de Pinto
  • Olinda Maria Rodrigues de Araújo
  • Éveny Cristine Luna de Oliveira
  • Sandra Luzinete Felix de Freitas
  • Anderson Fernandes da Silva
  • Abílio Torres dos Santos Neto
  • Adreia Insabralde de Queiroz Cardoso Federal University of Mato Grosso do Sul
  • Isabelle Campos de Azevedo Federal University of Rio Grande do Norte
  • Marcos Antonio Ferreira Júnior


Objective: Evaluating clinical and hematological-clinical parameters of patients with sickle cell anemia (SCA) before and after four years of using hydroxyurea (HU). 

Method: A retrospective cohort study implementing a quantitative, descriptive and analytical approach developed in two public teaching hospitals located in the Central-West region of Brazil, from November 2010 to October 2011. Data collection was performed through medical records of 32 patients with SCA to assess clinical and hematological parameters before and after HU treatment. The study was approved by the UFMS Ethics Committee under protocol number 1890/2010.

Results: All of the 32 patients were homozygous with a mean age in the prescription of hydroxyurea of 19.72±7.58 years, an initial dose of 15.59±4.27 mg/kg/day, and 22.48±5.35 mg/kg/day in the fourth year of treatment. Regarding the use of HU, average values of some hematological parameters presented a significant difference in the fourth year compared to the mean values prior to HU use, such as fetal hemoglobin (14.49±7.52%), red blood cells (2.54±0.38x1012/L), hematocrit (25.30±4.03%) and hemoglobin (9.22±3.34g/dL). 

Conclusion: Treatment with hydroxyurea showed a significant increase in fetal hemoglobin levels, increased hemoglobin, hematocrit and average corpuscular hemoglobin concentration, with reduced episodes of pain, infection and acute chest syndrome in such a way as to reaffirm its efficiency in treating these patients.

Keywords: Hemoglobin; Sickle Cell Anemia; Hydroxyurea.

Author Biographies

Adreia Insabralde de Queiroz Cardoso, Federal University of Mato Grosso do Sul

Federal University of Mato Grosso do Sul

Isabelle Campos de Azevedo, Federal University of Rio Grande do Norte
Nurse. Master's Student in Post-Graduate Program in Nursing of the Federal University of Rio Grande do Norte. Natal/RN, Brazil.


1. Costa FF. Anemia falciforme. In: Zago MA, Falcão RP, Pasquini R. Hematologia: Fundamentos e prática. São Paulo, Atheneu, 2004, 289-307.
2. Moreira AS, Silva RAA. Iron deficiency anemia in patients with sickle cell disease: the importance of assessing the iron nutritional status. Rev. Ciênc. Méd. Biol. 2014; 13(2):236-241.
3. Zago MA, Pinto ACS. The pathophysiology of sickle cell disease: from the genetic mutation to multiorgan disfunction. Rev. Bras. Hematol. Hemoter. 2007; 29(3):207-214.
4. Silva DG,  Marques IR. Intervenciones de enfermería durante las crisis de dolor en portadores de Anemía Falciforme. Rev. bras. enferm. 2007; 60(3):327-330.
5. Platt OS. Hydroxyurea for the treatment of sickle cell anemia. N. Engl. J. Med. 2008; 358:1362-1369.
6. Ivo ML. Hematologia: um olhar sobre a doença falciforme. Campo Grande (MS), UFMS, 2013. 289p.
7. Cordeiro RC, Ferreira SL, Santos ACC. The illness of women and men with sickle cell disease: a Grounded Theory study. Rev. Latino-Am. Enfermagem. 2015; 23(6):1113-20.
8. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N. Engl. J. Med., 1995; 332:1317-1322.
9. Davies SC, Gilmore, A. The role of hydroxyurea in management of sickle cell disease. Blood. 2003; 17(2):99-109.
10. Steinberg MH, Carthy WF, Castro O, Ballas SK, Armstrong FD, Smith W, Ataga K, Swerdlow P, Kutlar A, DeCastro L, Waclawiw MA. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol. 2010; 85(6):403–408.
11. Fitzhugh CD, Hsieh MM, Allen D, Coles WA, Seamon C, Ring M, Zhao X, Minniti CP, Rodgers GP, Schechter AN, Tisdale JF, Taylor JG. Hydroxyurea-increased fetal hemoglobin is associated with less organ damage and longer survival in adults with sickle cell anemia. PLoS ONE. 2015; 10(11): e0141706.
12. Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell, KL, James AH, Jordan L, Lanzkron SM, Lottenberg R, Savage WJ, Tanabe PJ, Ware RE, Murad MH, Goldsmith JC, Ortiz E, Fulwood R, Horton A, John-Sowah J. Management of Sickle Cell Disease: Summary of the 2014 Evidence-Based Report by Expert Panel Members. JAMA. 2014; 312(10):1033-1048.
13. Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. Portaria Nº 55, de 29 de janeiro de 2010. Aprova em forma de anexo desta Portaria o Protocolo Clínico e Diretrizes Terapêuticas - Doença Falciforme. Brasília (DF): Ministério da Saúde, 2010. Available from:
14. Ayres M, Ayres Jr M, Ayres DL, Santos AS. BioEstat 4.0: Aplicações estatísticas nas áreas das ciências biológicas e médicas. Belém: Sociedade Civil Mamirauá; Brasília: CNPq, 2005, 324 p.
15. Charache S, Dover GJ, Moore RD, Eckert S, Ballas SK, Koshy M, Milner PF, Orringer EP, Phillips G Jr, Platt OS. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood, 1992; 79(10):2555-2565.
16. Ware RE, Aygun B. Advances in the use of hydroxyurea. Hematology Am Soc Hematol Educ Prog. 2009; 62-69.
17. Kinney TR, Helms RW, O’Branski EE, Ohene-Frempong K, W Wang, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE. Safety of Hydroxyurea in Children with Sickle Cell Anemia: Results of the HUG-KIDS Study, a Phase I/II Trial. Pediatric Hydroxyurea Group. Blood.1999; 94(5):1550-1554.
18. Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest. 1984; 74(2):652-656.
19. Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H, Witkop C, Bass EB, Segal JB. Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med. 2008; 148(12):939-955.
20. Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive “switching” agent. The multicenter study of hydroxyurea in sickle cell anemia. Medicine, (Baltimore). 1996; 75(6):300-26.
21. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia − risks and benefits up to 9 years of treatment. JAMA 2003; 289(13):1645-1651.
22. Mousinho RRC, Cardoso GL, Sousa IEL, Martins PK. The importance of the evaluation of fetal hemoglobin in the clinical assessment of sickle cell disease. Rev. bras. hematol. hemoter; mar.-abr. 2008, 30(2):136-141.
How to Cite
BISPO, Ieda Maria Gonçalves Pacce et al. Clinical and Hematological Evaluation of Patients with Sickle Cell Anemia Before and After Four Years of Using Hydroxyurea. International Archives of Medicine, [S.l.], v. 10, june 2017. ISSN 1755-7682. Available at: <>. Date accessed: 12 nov. 2019. doi:

Most read articles by the same author(s)